TransMedics Group (NASDAQ:TMDX) Trading Down 6%

TransMedics Group, Inc. (NASDAQ:TMDX) shares dropped 6% during mid-day trading on Thursday . The stock traded as low as $141.48 and last traded at $141.98. Approximately 635,723 shares were traded during mid-day trading, a decline of 16% from the average daily volume of 759,709 shares. The stock had previously closed at $150.98.

Analyst Ratings Changes

Several analysts recently commented on TMDX shares. TD Cowen increased their target price on shares of TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a research note on Friday, June 7th. Needham & Company LLC started coverage on TransMedics Group in a research note on Wednesday, August 21st. They set a “buy” rating and a $208.00 price objective for the company. Stephens boosted their target price on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Oppenheimer upped their target price on TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. Finally, Cantor Fitzgerald started coverage on TransMedics Group in a research note on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, TransMedics Group has an average rating of “Moderate Buy” and a consensus target price of $171.44.

TransMedics Group Trading Down 2.4 %

The company has a market cap of $4.67 billion, a PE ratio of -411.41 and a beta of 1.99. The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37. The company has a 50 day simple moving average of $154.82 and a two-hundred day simple moving average of $124.33.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The firm had revenue of $114.30 million for the quarter, compared to the consensus estimate of $98.84 million. During the same period in the previous year, the firm posted ($0.03) earnings per share. The firm’s revenue was up 117.7% on a year-over-year basis. Sell-side analysts forecast that TransMedics Group, Inc. will post 1.21 EPS for the current year.

Insider Buying and Selling

In other news, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $156.77, for a total transaction of $463,725.66. Following the completion of the sale, the insider now directly owns 20,843 shares in the company, valued at approximately $3,267,557.11. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other TransMedics Group news, insider Anil P. Ranganath sold 4,289 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $152.20, for a total transaction of $652,785.80. Following the transaction, the insider now directly owns 8,893 shares in the company, valued at $1,353,514.60. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $156.77, for a total value of $463,725.66. Following the completion of the sale, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $3,267,557.11. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 61,247 shares of company stock worth $9,551,089. Corporate insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in TransMedics Group by 1.3% during the first quarter. Vanguard Group Inc. now owns 1,889,094 shares of the company’s stock valued at $139,680,000 after purchasing an additional 23,979 shares during the last quarter. Driehaus Capital Management LLC raised its holdings in TransMedics Group by 15.8% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after acquiring an additional 202,867 shares during the period. Eventide Asset Management LLC boosted its holdings in TransMedics Group by 7.4% during the fourth quarter. Eventide Asset Management LLC now owns 994,240 shares of the company’s stock valued at $78,475,000 after acquiring an additional 68,884 shares during the period. First Light Asset Management LLC grew its position in shares of TransMedics Group by 22.0% in the fourth quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock valued at $59,538,000 after purchasing an additional 136,217 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of TransMedics Group by 3.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 730,010 shares of the company’s stock worth $53,977,000 after purchasing an additional 21,737 shares during the period. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.